Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

Similar articles for PubMed (Select 14749476)

1.

The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.

Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ.

Mol Cancer Ther. 2004 Jan;3(1):59-70. Erratum in: Mol Cancer Ther. 2009 Feb;8(2):479.

2.

Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts.

Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ.

Mol Cancer Ther. 2003 Sep;2(9):835-43.

3.

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.

Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, Adams J, Callery MP.

J Cell Biochem. 2001 Apr 2-27;82(1):110-22.

PMID:
11400168
4.

The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.

Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP, McConkey DJ.

Mol Cancer Ther. 2004 Mar;3(3):279-90.

5.

Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.

Bae SH, Ryoo HM, Kim MK, Lee KH, Sin JI, Hyun MS.

Oncol Rep. 2008 Apr;19(4):1027-32.

PMID:
18357392
6.

Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells.

Canfield SE, Zhu K, Williams SA, McConkey DJ.

Mol Cancer Ther. 2006 Aug;5(8):2043-50.

7.

Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.

Wang C, Gao D, Guo K, Kang X, Jiang K, Sun C, Li Y, Sun L, Shu H, Jin G, Sun H, Wu W, Liu Y.

BMC Cancer. 2012 May 4;12:166. doi: 10.1186/1471-2407-12-166.

8.

Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts.

Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, Elliott P, Adams J, McConkey DJ.

Mol Cancer Ther. 2002 Dec;1(14):1243-53.

9.

Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.

Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K Jr, Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL, McConkey DJ.

Cancer Res. 2006 Apr 1;66(7):3773-81.

10.

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.

Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS.

J Neurosurg. 2013 Dec;119(6):1415-23. doi: 10.3171/2013.7.JNS1323. Epub 2013 Oct 4.

PMID:
24093630
11.

Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.

Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R, Logsdon CD, Abbruzzese JL, McConkey DJ.

Mol Cancer Ther. 2006 Sep;5(9):2251-60.

12.

Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.

Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M, Piccardi F, Cilli M, Pezzolo A, Corrias MV, Pistoia V, Ribatti D, Pagnan G, Ponzoni M.

J Natl Cancer Inst. 2006 Aug 16;98(16):1142-57.

14.

Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.

Lee JK, Ryu JK, Yang KY, Woo SM, Park JK, Yoon WJ, Lee SH, Jeong KS, Kim YT, Yoon YB.

Pancreas. 2011 Aug;40(6):966-73. doi: 10.1097/MPA.0b013e3182156d5a.

PMID:
21487323
15.

The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.

Luo P, Lin M, Li L, Yang B, He Q.

PLoS One. 2011;6(11):e27298. doi: 10.1371/journal.pone.0027298. Epub 2011 Nov 7.

16.

Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.

Märten A, Zeiss N, Serba S, Mehrle S, von Lilienfeld-Toal M, Schmidt J.

Mol Cancer Ther. 2008 Nov;7(11):3624-31. doi: 10.1158/1535-7163.MCT-08-0393.

17.

Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.

Uddin S, Ahmed M, Bavi P, El-Sayed R, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Hussain AR, Al-Kuraya KS.

Cancer Res. 2008 May 1;68(9):3379-88. doi: 10.1158/0008-5472.CAN-07-6109.

18.

Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.

Tamatani T, Takamaru N, Hara K, Kinouchi M, Kuribayashi N, Ohe G, Uchida D, Fujisawa K, Nagai H, Miyamoto Y.

Int J Oncol. 2013 Mar;42(3):935-44. doi: 10.3892/ijo.2013.1786. Epub 2013 Jan 22.

PMID:
23340716
19.

Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells.

Papageorgiou A, Kamat A, Benedict WF, Dinney C, McConkey DJ.

Mol Cancer Ther. 2006 Dec;5(12):3032-41. Erratum in: Mol Cancer Ther. 2009 Feb;8(2):480.

20.

Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.

Nakata W, Hayakawa Y, Nakagawa H, Sakamoto K, Kinoshita H, Takahashi R, Hirata Y, Maeda S, Koike K.

Int J Oncol. 2011 Dec;39(6):1529-36. doi: 10.3892/ijo.2011.1141. Epub 2011 Jul 22.

PMID:
21785822
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk